FDA's expedited approval program is what the patient ordered

09/13/2012 | Forbes

Recent criticism that the FDA is sacrificing patient safety in a rush to approve drugs is unfounded, writes John L. LaMattina, former president of Pfizer Global Research and Development. Patients with life-threatening illnesses want access to promising medicines and are willing risk serious side effects, LaMattina writes. Moreover, the FDA attaches stringent requirements for risk evaluation and mitigation to expedited approval, he writes.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD